Testosterone undecanoate oral - TesoRx

Drug Profile

Testosterone undecanoate oral - TesoRx

Alternative Names: Low-T therapy - TesoRx; Modified testosterone - TesoRx; Oral TRT therapy - TesoRx; Testosterone replacement therapy - TesoRx; THG 1001; TSX-011

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator TesoRx
  • Developer ASKA Pharmaceutical; TesoRx
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 27 Apr 2017 ASKA and TesoRx plans a phase I/IIa trial for Hypogonadism in USA and Japan later 2017 (PO)
  • 19 Jan 2017 Testosterone undecanoate oral of TesoRx is available for licensing in (excluding Japan) as of 09 Jan 2017. http://www.tesorx.com/
  • 09 Jan 2017 TesoRx Pharma and ASKA Pharmaceutical agree to co-develop and co-promote testosterone undecanoate in Japan for Hypogonadism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top